Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Total Current Liabilities (2016 - 2025)

Medifast's Total Current Liabilities history spans 16 years, with the latest figure at $43.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 33.04% year-over-year to $43.0 million; the TTM value through Dec 2025 reached $43.0 million, down 33.04%, while the annual FY2025 figure was $43.0 million, 33.04% down from the prior year.
  • Total Current Liabilities reached $43.0 million in Q4 2025 per MED's latest filing, down from $46.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $188.2 million in Q2 2022 to a low of $43.0 million in Q4 2025.
  • Average Total Current Liabilities over 5 years is $111.4 million, with a median of $112.5 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 77.1% in 2021, then tumbled 41.41% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $169.8 million in 2021, then fell by 17.04% to $140.9 million in 2022, then crashed by 34.49% to $92.3 million in 2023, then tumbled by 30.49% to $64.2 million in 2024, then tumbled by 33.04% to $43.0 million in 2025.
  • Per Business Quant, the three most recent readings for MED's Total Current Liabilities are $43.0 million (Q4 2025), $46.7 million (Q3 2025), and $46.2 million (Q2 2025).